• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 从无 COVID-19 症状者传播。

SARS-CoV-2 Transmission From People Without COVID-19 Symptoms.

机构信息

COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.

Office of the Deputy Directory for Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.

出版信息

JAMA Netw Open. 2021 Jan 4;4(1):e2035057. doi: 10.1001/jamanetworkopen.2020.35057.

DOI:10.1001/jamanetworkopen.2020.35057
PMID:33410879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7791354/
Abstract

IMPORTANCE

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology of coronavirus disease 2019 (COVID-19), is readily transmitted person to person. Optimal control of COVID-19 depends on directing resources and health messaging to mitigation efforts that are most likely to prevent transmission, but the relative importance of such measures has been disputed.

OBJECTIVE

To assess the proportion of SARS-CoV-2 transmissions in the community that likely occur from persons without symptoms.

DESIGN, SETTING, AND PARTICIPANTS: This decision analytical model assessed the relative amount of transmission from presymptomatic, never symptomatic, and symptomatic individuals across a range of scenarios in which the proportion of transmission from people who never develop symptoms (ie, remain asymptomatic) and the infectious period were varied according to published best estimates. For all estimates, data from a meta-analysis was used to set the incubation period at a median of 5 days. The infectious period duration was maintained at 10 days, and peak infectiousness was varied between 3 and 7 days (-2 and +2 days relative to the median incubation period). The overall proportion of SARS-CoV-2 was varied between 0% and 70% to assess a wide range of possible proportions.

MAIN OUTCOMES AND MEASURES

Level of transmission of SARS-CoV-2 from presymptomatic, never symptomatic, and symptomatic individuals.

RESULTS

The baseline assumptions for the model were that peak infectiousness occurred at the median of symptom onset and that 30% of individuals with infection never develop symptoms and are 75% as infectious as those who do develop symptoms. Combined, these baseline assumptions imply that persons with infection who never develop symptoms may account for approximately 24% of all transmission. In this base case, 59% of all transmission came from asymptomatic transmission, comprising 35% from presymptomatic individuals and 24% from individuals who never develop symptoms. Under a broad range of values for each of these assumptions, at least 50% of new SARS-CoV-2 infections was estimated to have originated from exposure to individuals with infection but without symptoms.

CONCLUSIONS AND RELEVANCE

In this decision analytical model of multiple scenarios of proportions of asymptomatic individuals with COVID-19 and infectious periods, transmission from asymptomatic individuals was estimated to account for more than half of all transmissions. In addition to identification and isolation of persons with symptomatic COVID-19, effective control of spread will require reducing the risk of transmission from people with infection who do not have symptoms. These findings suggest that measures such as wearing masks, hand hygiene, social distancing, and strategic testing of people who are not ill will be foundational to slowing the spread of COVID-19 until safe and effective vaccines are available and widely used.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd75/7791354/ff860503ecaf/jamanetwopen-e2035057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd75/7791354/de539bfc6ca7/jamanetwopen-e2035057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd75/7791354/ff860503ecaf/jamanetwopen-e2035057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd75/7791354/de539bfc6ca7/jamanetwopen-e2035057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd75/7791354/ff860503ecaf/jamanetwopen-e2035057-g002.jpg
摘要

重要性

严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)是导致 2019 年冠状病毒病(COVID-19)的病因,易于在人与人之间传播。COVID-19 的最佳控制取决于将资源和健康信息引导至最有可能预防传播的缓解措施,但这些措施的相对重要性存在争议。

目的

评估社区中可能因无症状者传播 SARS-CoV-2 的比例。

设计、地点和参与者:本决策分析模型评估了在一系列情况下,从无症状、从未出现症状和出现症状的个体中传播 SARS-CoV-2 的比例,其中从不出现症状的人(即无症状)的传播比例和感染期根据已发表的最佳估计值而变化。对于所有估计值,使用荟萃分析的数据将潜伏期设定为中位数 5 天。感染期持续时间保持在 10 天,而发病高峰期在潜伏期中位数的正负 2 天内波动,为 3 至 7 天。SARS-CoV-2 的总体比例在 0%至 70%之间变化,以评估广泛的可能比例。

主要结果和测量指标

从无症状、从未出现症状和出现症状的个体中传播 SARS-CoV-2 的水平。

结果

模型的基线假设是发病高峰期出现在症状出现的中位数,30%的感染者从未出现症状,其传染性与出现症状的感染者相同,传染性为 75%。这些基线假设综合表明,从未出现症状的感染者可能占所有传播的约 24%。在这种基本情况下,所有传播的 59%来自无症状传播,其中 35%来自发病前个体,24%来自从未出现症状的个体。在这些假设的广泛值下,估计至少有 50%的新 SARS-CoV-2 感染源自接触无症状感染者。

结论和相关性

在这个关于 COVID-19 无症状个体比例和感染期的多个场景的决策分析模型中,来自无症状个体的传播估计占所有传播的一半以上。除了识别和隔离有症状的 COVID-19 患者外,有效控制传播还需要降低无症状感染者的传播风险。这些发现表明,佩戴口罩、手部卫生、社交距离以及对未患病者进行有针对性的检测等措施将成为减缓 COVID-19 传播的基础,直到安全有效的疫苗广泛使用。

相似文献

1
SARS-CoV-2 Transmission From People Without COVID-19 Symptoms.SARS-CoV-2 从无 COVID-19 症状者传播。
JAMA Netw Open. 2021 Jan 4;4(1):e2035057. doi: 10.1001/jamanetworkopen.2020.35057.
2
High infectiousness immediately before COVID-19 symptom onset highlights the importance of continued contact tracing.在 COVID-19 症状出现之前具有很高的传染性,这凸显了持续进行接触者追踪的重要性。
Elife. 2021 Apr 26;10:e65534. doi: 10.7554/eLife.65534.
3
Universal screening for SARS-CoV-2 infection: a rapid review.SARS-CoV-2 感染的普遍筛查:快速综述。
Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718.
4
[Transmission of SARS-CoV-2 through contact with a SARS-CoV-2-infected individual in the presymptomatic or asymptomatic state in Japan: A case series].[日本SARS-CoV-2感染个体在症状前期或无症状状态下SARS-CoV-2的传播:病例系列]
Nihon Koshu Eisei Zasshi. 2021 Aug 11;68(8):550-558. doi: 10.11236/jph.20-145. Epub 2021 May 14.
5
Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols.飞沫和气溶胶传播 SARS-CoV-2 的传染性和脱落的异质性。
Elife. 2021 Apr 16;10:e65774. doi: 10.7554/eLife.65774.
6
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.无症状和出现症状前 SARS-CoV-2 感染的发生和传播潜力:一项实时系统评价和荟萃分析。
PLoS Med. 2020 Sep 22;17(9):e1003346. doi: 10.1371/journal.pmed.1003346. eCollection 2020 Sep.
7
Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy.意大利接触确诊 SARS-CoV-2 感染患者的密切接触者中,年龄与出现症状和重症疾病的可能性之间的关系。
JAMA Netw Open. 2021 Mar 1;4(3):e211085. doi: 10.1001/jamanetworkopen.2021.1085.
8
Evidence for transmission of COVID-19 prior to symptom onset.有证据表明新冠病毒在症状出现之前就已经传播。
Elife. 2020 Jun 22;9:e57149. doi: 10.7554/eLife.57149.
9
Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review.新冠病毒(SARS-CoV-2)的潜伏和无症状感染者的传播:系统综述。
Clin Microbiol Infect. 2022 Feb;28(2):178-189. doi: 10.1016/j.cmi.2021.10.015. Epub 2021 Oct 29.
10
Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission.对医护人员进行 SARS-CoV-2 筛查突出了无症状携带在 COVID-19 传播中的作用。
Elife. 2020 May 11;9:e58728. doi: 10.7554/eLife.58728.

引用本文的文献

1
Analyzing SARS-CoV-2 case numbers and clustering to predict a nursing home outbreak.分析新冠病毒病例数及聚类情况以预测养老院疫情爆发。
Aging Clin Exp Res. 2025 Aug 31;37(1):265. doi: 10.1007/s40520-025-03155-9.
2
Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach.一种新型严重急性呼吸综合征冠状病毒2变体对人群的影响:一种数学建模方法。
Math Comput Appl. 2021 Jun;26(2). doi: 10.3390/mca26020025. Epub 2021 Mar 27.
3
Adaptive strategies for the deployment of rapid diagnostic tests for COVID-19: a modelling study.

本文引用的文献

1
Presymptomatic transmission of SARS-CoV-2 infection: a secondary analysis using published data.新型冠状病毒2型感染的症状前传播:一项利用已发表数据的二次分析
BMJ Open. 2021 Jun 28;11(6):e041240. doi: 10.1136/bmjopen-2020-041240.
2
Relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: a rapid scoping review.无症状 SARS-CoV-2 感染者与有症状感染者的相对传染性:快速范围综述。
BMJ Open. 2021 May 4;11(5):e042354. doi: 10.1136/bmjopen-2020-042354.
3
Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review.
2019年冠状病毒病快速诊断检测部署的适应性策略:一项建模研究
Gates Open Res. 2025 May 27;7:6. doi: 10.12688/gatesopenres.14202.2. eCollection 2023.
4
An agent-based model for household COVID-19 transmission in Gauteng, South Africa.南非豪登省家庭新冠病毒传播的基于主体的模型。
PLoS One. 2025 Jul 16;20(7):e0325619. doi: 10.1371/journal.pone.0325619. eCollection 2025.
5
Unifying human infectious disease models and real-time awareness of population- and subpopulation-level intervention effectiveness.统一人类传染病模型以及对人群和亚人群层面干预效果的实时认知。
R Soc Open Sci. 2025 Jun 18;12(6):241964. doi: 10.1098/rsos.241964. eCollection 2025 Jun.
6
Effectiveness of SARS-CoV-2 testing strategies: A scoping review.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)检测策略的有效性:一项范围综述。
Cochrane Evid Synth Methods. 2023 Nov 21;1(9):e12030. doi: 10.1002/cesm.12030. eCollection 2023 Nov.
7
Remote early detection of SARS-CoV-2 infections using a wearable-based algorithm: Results from the COVID-RED study, a prospective randomised single-blinded crossover trial.使用基于可穿戴设备的算法对SARS-CoV-2感染进行远程早期检测:COVID-RED研究结果,一项前瞻性随机单盲交叉试验。
PLoS One. 2025 Jun 5;20(6):e0325116. doi: 10.1371/journal.pone.0325116. eCollection 2025.
8
Rapid and highly sensitive immunoassay using an ultra-thin immuno-wall microfluidic device with a sequential fluorescence signal increment method.使用具有顺序荧光信号增量法的超薄免疫壁微流控装置的快速且高灵敏度免疫测定。
Anal Bioanal Chem. 2025 May 28. doi: 10.1007/s00216-025-05916-x.
9
Kinetics of SARS-CoV-2 Shedding in Nursing Home Residents and Staff.养老院居民和工作人员中新型冠状病毒2型脱落的动力学
J Am Geriatr Soc. 2025 Jul;73(7):2127-2136. doi: 10.1111/jgs.19499. Epub 2025 May 2.
10
Study on the detection rate, genetic polymorphism, viral load, persistent infection capacity, and pathogenicity of human papillomavirus type 33.人乳头瘤病毒33型的检出率、基因多态性、病毒载量、持续感染能力及致病性研究
Virol J. 2025 Apr 26;22(1):121. doi: 10.1186/s12985-025-02752-4.
与累计和推断的 COVID-19 病例相比,SARS-CoV-2 感染的血清流行率比较:系统评价。
PLoS One. 2021 Apr 2;16(4):e0248946. doi: 10.1371/journal.pone.0248946. eCollection 2021.
4
Analysis of SARS-CoV-2 Transmission in Different Settings, Brunei.对文莱不同环境中 SARS-CoV-2 传播的分析。
Emerg Infect Dis. 2020 Nov;26(11):2598-2606. doi: 10.3201/eid2611.202263. Epub 2020 Oct 9.
5
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.无症状和出现症状前 SARS-CoV-2 感染的发生和传播潜力:一项实时系统评价和荟萃分析。
PLoS Med. 2020 Sep 22;17(9):e1003346. doi: 10.1371/journal.pmed.1003346. eCollection 2020 Sep.
6
Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research.COVID-19 的潜伏期:一项针对观察性研究的快速系统评价和荟萃分析。
BMJ Open. 2020 Aug 16;10(8):e039652. doi: 10.1136/bmjopen-2020-039652.
7
Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea.韩国社区治疗中心中无症状和有症状的 SARS-CoV-2 感染患者的临床病程和分子病毒脱落情况。
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452. doi: 10.1001/jamainternmed.2020.3862.
8
Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases.推断 SARS-CoV-2 的传染期:对无症状和有症状 COVID-19 病例的现有证据进行快速范围审查和分析。
BMJ Open. 2020 Aug 5;10(8):e039856. doi: 10.1136/bmjopen-2020-039856.
9
Evidence for transmission of COVID-19 prior to symptom onset.有证据表明新冠病毒在症状出现之前就已经传播。
Elife. 2020 Jun 22;9:e57149. doi: 10.7554/eLife.57149.
10
Age-dependent effects in the transmission and control of COVID-19 epidemics.年龄相关因素对 COVID-19 疫情传播和防控的影响。
Nat Med. 2020 Aug;26(8):1205-1211. doi: 10.1038/s41591-020-0962-9. Epub 2020 Jun 16.